H-Index
70
Scimago Lab
powered by Scopus
Clarivate
Analytics
Formerly the IP & Science
business of Thomson Reuters

Logo




eISSN: 1643-3750

Get your full text copy in PDF

A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry

Piotr Potemski, Elżbieta Płuciennik, Andrzej K. Bednarek, Renata Kusińska, Grażyna Pasz-Walcza, Dorota Jesionek-Kupnicka, Cezary Watała, Radzisław Kordek

Med Sci Monit 2006; 12(12): MT57-61

ID: 469712


Background: The most commonly used methods for detecting HER2 gene amplifi cation in breast cancer are immunohistochemistry and fl uorescence in-situ hybridization. The aim of this retrospective study was to assess HER2 expression by real-time RT-PCR.
Material/Methods: Expression of HER2 was analyzed by real-time RT-PCR and immunohistochemistry in specimens of invasive ductal breast cancer tissue obtained from 131 women during radical mastectomy.
Results: There was a highly signifi cant difference in mean relative gene expression between HER2-positive and HER2-negative patients as assessed by immunostaining (22.10±41.89 vs. 3.17±8.76; p<0.001). With a median follow-up of 56 months, the cancer-specific survival of HER2-positive patients assessed by RT-PCR was worse in all cases and in the node-positive group. In multivariate analysis, HER2 status was an independent prognostic factor in all patients.
Conclusions:     Real-time RT-PCR is a valuable method for determining HER2 status, but the selection of the cut-off point of the relative gene expression differentiating between HER2-negative and -positive tumors is essential.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree